Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX 14:24:48 2024-07-17 EDT 5-day change 1st Jan Change
157 USD +4.00% Intraday chart for Johnson & Johnson +4.93% +0.03%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Higher Wednesday Afternoon MT
Sector Update: Health Care MT
Fed Governor Waller's Comments, Earnings Leave Equities Mixed; Nvidia Slides MT
Megacap tech, chip stock rout drags Nasdaq to two-week low; Dow outperforms RE
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Top Midday Stories: Chip Stocks Fall; MBA US Mortgage Applications Rebound; Johnson & Johnson, Elevance Health Q2 Earnings Rise; Prologis Posts Q2 Beat; VF to Sell Supreme Brand to EssilorLuxottica MT
Stocks in motion: VF Corp and Johnson & Johnson stand out Our Logo
Trending : Johnson & Johnson Beats 2Q Sales Guidance DJ
Johnson & Johnson Cuts Full-Year Earnings Outlook Following Second-Quarter Beat MT
Earnings reports take center stage as tech stocks tumble Our Logo
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday MT
Wall Street set to fall as megacap chip, tech stocks tumble RE
Transcript : Johnson & Johnson, Q2 2024 Earnings Call, Jul 17, 2024
Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex MT
Stock Futures Decline as Traders Await More Earnings; Asia, Europe Churn MT
Johnson & Johnson Maintains Quarterly Dividend at $1.24 per Share, Payable Sept. 10 to Shareholders of Record on Aug. 27 MT
J&J: Quarterly adjusted EPS up 10.2 CF
Johnson & Johnson Q2 Adjusted Earnings, Revenue Rise; Lowers Full-Year Earnings Guidance MT
Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024 CI
Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q2 Revenue $22.45B MT
Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q2 EPS $2.82 MT
Johnson & Johnson Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Wall St futures slump after rally as tech stocks slide RE
EU court criticizes Commission over handling of COVID vaccine contracts RE
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC CI
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
151 USD
Average target price
171.5 USD
Spread / Average Target
+13.56%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Johnson & Johnson Cuts Full-Year Earnings Outlook Following Second-Quarter Beat